The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review

Gordon, 2001, Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer, J Clin Oncol, 19, 843, 10.1200/JCO.2001.19.3.843 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 Yang, 2003, A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer, New Engl J Med, 349, 427, 10.1056/NEJMoa021491 Miller, 2005, Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer, J Clin Oncol, 23, 792, 10.1200/JCO.2005.05.098 Kindler, 2005, Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer, J Clin Oncol, 23, 8033, 10.1200/JCO.2005.01.9661 Johnson, 2004, Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer, J Clin Oncol, 22, 2184, 10.1200/JCO.2004.11.022 Kabbinavar, 2003, Phase 2 randomised trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer, J Clin Oncol, 21, 60, 10.1200/JCO.2003.10.066 Wright, 2006, A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent, platinum-resistant ovarian cancer, J Clin Oncol, 24 Friberg, 2006, Bevacizumab (B) plus erlotinib (E) for patients (pts) with recurrent ovarian (OC) and fallopian tube (FT) cancer, Preliminary results of a multi-center phase II trial, J Clin Oncol, 24 Cannistra, 2006, Bevacizumab in patients with advanced platinum-resistant ovarian cancer, J Clin Oncol, 24 Jayson, 2005, Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer, Eur J Cancer, 41, 555, 10.1016/j.ejca.2004.11.021 Dupont, 2004, Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (s) to patients (pts) with advanced solid malignancies, Clin Oncol, 22 Dupont, 2005, Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors, J Clin Oncol, 23 Camidge, 2006, A phase I dose-escalation study of weekly IMC-1121B, a human IgG1 antivascular endothelial growth factor receptor 2 monoclonal antibody in patients with advance cancer, J Clin Oncol, 24 Sane, 2004, Angiogenic growth factors and hypertension, Angiogenesis, 7, 193, 10.1007/s10456-004-2699-3 Maitland, 2006, Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway, J Clin Oncol, 24 Eskens, 2005, An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors, J Clin Oncol, 24 Rini, 2005, AG–013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC), J Clin Oncol, 23 Minami, 2003, A phase I study of an oral VEGF tyrosine kinase inhibitor ZD6474, in japanese patients with solid tumors, Proc Am Soc Clin Oncol George, 2003, Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma, Proc Am Soc Clin Oncol, 22 Curwen, 2005, Management of Hypertension Induced by AZD2171, an Oral, Highly Potent and Reversible VEGFR Signaling Inhibitor in Rat, Clin Cancer Res, 11, 9119s Nadar, 2005, Plasma markers of angiogenesis in pregnancy induced hypertension, Thromb Haemost, 94, 1071, 10.1160/TH05-03-0167 Kuenen, 2003, Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416, J Clin Oncol, 21, 2192, 10.1200/JCO.2003.08.046 Hambleton, 2004, Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation, J Clin Oncol, 22 Scappaticci, 2005, Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab, J Surg Oncol, 91, 173, 10.1002/jso.20301 Rini, 2006, Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC), J Clin Oncol, 24 Drevs, 2005, Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced solid tumors, J Clin Oncol, 23 Rahbar, 2005, Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis, Ann Otol Rhinol Laryngol, 114, 289, 10.1177/000348940511400407 Bulut, 2006, Vascular endothelial growth factor (VEGF164) ameliorates intestinal epithelial injury in vitro in IEC-18 and Caco-2 monolayers via induction of TGF-beta release from epithelial cells, Scand J Gastroenterol, 41, 687, 10.1080/00365520500408634 Rugo, 2005, Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors, pharmacokinetic and clinical results, J Clin Oncol, 23, 5474, 10.1200/JCO.2005.04.192 Basson, 2002, Gut mucosal healing, is the science relevant?, Am J Pathol, 161, 1101, 10.1016/S0002-9440(10)64385-4 Szabo, 1998, Vascular approach to gastroduodenal ulceration, new studies with endothelind and VEGF, Dig Dis Sci, 43, 40S Matsuura, 2005, Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis, Gastroenterology, 128, 975, 10.1053/j.gastro.2005.01.006 Danese, 2006, Angiogenesis as a novel component of inflammatory bowel disease pathogenesis, Gastroenterology, 130, 2060, 10.1053/j.gastro.2006.03.054 Taha, 2004, Vascular endothelial growth factor (VEGF) a possible mediator of inflammation and mucosal permeability in patients with collagenous colitis, Dig Dis Sci, 49, 109, 10.1023/B:DDAS.0000011611.92440.f2 Desai, 2005, Hypothyroidism may accompany SU11248 therapy in a subset of patients (pts) with metastatic (met) gastrointestinal stromal tumors (GIST) and is manageable with replacement therapy, J Clin Oncol, 23 Schoeffski, 2006, Sunitinib-related thyroid dysfunction, A single-center retrospective and prospective evaluation, J Clin Oncol, 24 Shaheen, 2006, Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib, J Clin Oncol, 24 Ramsden, 2000, Angiogenesis in the thyroid gland, J Endocrinol, 166, 475, 10.1677/joe.0.1660475 Kim, 2006, An orally administered multi-target tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/PTC kinases, J Clin Endocrinol Metab. Carlomagno, 2006, BAY 43-9006 inhibition of oncogenic RET mutants, J Natl Cancer Inst, 98, 326, 10.1093/jnci/djj069 Iitaka, 1998, Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves’ disease and Hashimoto’s thyroiditis, J Clin Endocrin Met, 83, 3908, 10.1210/jc.83.11.3908 Tsuchihashi, 2006, Vascular endothelial growth factor antagonist modulates leukocyte trafficking and protects mouse livers against ischemia/reperfusion injury, Am J Pathol, 168, 695, 10.2353/ajpath.2006.050759 Tsurui, 2005, Dual role of vascular endothelial growth factor in hepatic ischemia-reperfusion injury, Transplant, 79, 1110, 10.1097/01.TP.0000161627.84481.5E LeCouter, 2003, Angiogenesis-independent endothelial protection of liver, role of VEGFR-1, Science, 299, 889, 10.1126/science.1079562 Marino, 2006, New model of liver regeneration induced through use of vascular endothelial growth factor, Transplant Proc, 38, 1193, 10.1016/j.transproceed.2006.02.022 Donahower, 2006, Vascular endothelial growth factor and hepatocyte regeneration in acetaminophen toxicity, Am J Physiol Gastrointest Liver Physiol., 291, G102, 10.1152/ajpgi.00575.2005 Assy, 1999, Effect of vascular endothelial growth factor on hepatic regenerative activity following partial hepatectomy in rats, J Hepatol, 30, 911, 10.1016/S0168-8278(99)80147-0 Thomas, 2005, Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTK787/ZK 222584 Administered Twice Daily in Patients With Advanced Cancer, J Clin Oncol, 23, 4162, 10.1200/JCO.2005.09.034 Joensuu, 2006, A phase II, open-label study of PTK787/ZK 222584 in the treatment of metastatic gastrointestinal stromal tumors (GISTs) resistant to imatinib mesylate, J Clin Oncol, 24 Zachary, 2005, Neuroprotective role of vascular endothelial growth factor, signalling mechanisms, biological function, and therapeutic potential, Neurosignals, 14, 207, 10.1159/000088637 Brockington, 2004, Vascular endothelial growth factor and the nervous system, Neuropathol Appl Neurobiol, 30, 4246, 10.1111/j.1365-2990.2004.00600.x Gora-Kupilas, 2005, The neuroprotective function of vascular endothelial growth factor (VEGF), Folia Neuropathol, 43, 31 Nagore, 2000, Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Incidence, recognition and management, Am J Clin Dermatol, 1, 225, 10.2165/00128071-200001040-00004 Kara, 2006, Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction, Breast, 15, 414, 10.1016/j.breast.2005.07.007 Reardon, 2005, A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients, J Clin Oncol, 23 Martinelli, 2005, AEE 788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, preliminary phase I results, J Clin Oncol, 23 Kim, 2005, A Phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer, J Clin Oncol, 23 Rosen, 2005, Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors, J Clin Oncol, 23 Fujisaka, 2005, Safety and pharmacokinetics of AMG 706 in Japanese patients with advanced solid tumors, Clin Cancer Res, 11, 8965s Medinger, 2004, Phase I dose-escalation study of the highly potent VEGF receptor kinase inhibitor, AZD2171, in patients with advanced cancers with liver metastases, J Clin Oncol, 22 Ryan, 2005, Phase I evaluation of AZD 2171, a highly potent VEGFR tyrosine kinase inhibitor, in patients with advanced prostate adenocarcinoma, Clin Cancer Res, 11, 8965s Laurie, 2006, J Clin Oncol, 24 Holden, 2005, Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors, Ann Oncol, 16, 1391, 10.1093/annonc/mdi247 Johnson, 2005, Preliminary phase II safety evaluation of ZD6474 in combination with carboplatin and paclitaxel, as first line treatment with in patients with NSCLC, J Clin Oncol, 23 Wells, 2006, A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer, J Clin Oncol, 24 Heymach, 2006, A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC, Follow-up results, J Clin Oncol, 24 Strumberg, 2003, Final report of the phase I clinical program of the novel raf kinase inhibitor BAY 43-9006 in patients with refractory solid tumors, Proc Am Soc Clin Oncol Minami, 2005, A phase I study of BAY 43-9006, a dual inhibitor of Raf and VEGFR kinases, in Japanese patients with solid tumors, J Clin Oncol, 23 Flaherty, 2005, Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma, J Clin Oncol, 23 Wong, 2003, Final results of a phase I study to determine the safety, maximum tolerated dose, pharmacokinetics and pharmacodynamics of BAY 43-9006 in repeated cycles of 1 week on / 1 week off in patients with advanced, refractory solid tumors, Proc Am Soc Clin Oncol Strumberg, 2002, Final results of a phase I pharmacokinetic and pharmacodynamic study of the raf kinase inhibitor BAY 43-9006 in patients with solid tumors, Proc Am Soc Clin Oncol Moore, 2002, Phase I study of the Raf-1 kinase inhibitor BAY 43-9006 in patients with advanced refractory solid tumors, Proc Am Soc Clin Oncol, 10.1090/S0002-9939-02-06376-1 Gatzemeier, 2006, Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma, J Clin Oncol, 24 Hardin, 2006, A phase II trial of BAY 43-9006 in metastatic melanoma with molecularly characterized B-Raf status, J Clin Oncol, 24 Williamson, 2006, A phase II trial of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC), A Southwest Oncology Group (SWOG) trial, J Clin Oncol, 24 Kloos, 2006, Significant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC), Updated results of a phase II study, J Clin Oncol, 24 Moreno-Aspitia, 2006, BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane, J Clin Oncol, 24 Liu, 2006, A phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC), J Clin Oncol, 24 Gelderblom, 2006, Phase I, safety, pharmacokinetic and biomarker study of BAY 57-9352, an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors, J Clin Oncol, 24 Mross, 2006, Phase I study of BAY 57-9352, a VEGFR-2 inhibitor, in cycles of 14 days on/7 days off in patients with advanced solid tumors, J Clin Oncol, 24 Mross, 2005, A clinical phase I pharmacokinetic (PK) and pharmacodynamic study of twice daily BIBF 1120 in advanced cancer patients, J Clin Oncol, 23 Mross, 2005, Safety, pharmacokinetics and pharmacodynamics (DCE-MRI) in patients with metastatic colorectal cancer treated with BIBF 1120, the first triple angiokinase inhibitor, Clin Cancer Res, 11 Lee, 2006, A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI), J Clin Oncol, 24 Rosen, 2006, Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors, J Clin Oncol, 24 Sarker, 2006, A phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of CHIR-258, a novel oral multiple receptor tyrosine kinase (RTK) inhibitor, J Clin Oncol, 24 Tolcher, 2002, A phase I and biologic correlative study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients (pts) with advanced solid tumors, Proc Am Soc Clin Oncol Cohen, 2004, Phase I trial of oral CP-547,632 (VEGFR2) in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC), J Clin Oncol, 22 Suttle, 2004, Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors, J Clin Oncol, 22 Hurwitz, 2005, Safety, tolerability and pharmacokinetics of oral administration of GW 786034 in pts with solid tumors, J Clin Oncol, 23 Drevs, 2003, Phase I dose-escalation and pharmacokinetic (PK) study of the VEGF inhibitor PTK787/ZK 222584 (PTK/ZK) in patients with liver metastases, Proc Am Soc Clin Oncol, 22 Gauler, 2006, Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 orally administered once daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB or stage IV non-small cell lung cancer (NSCLC), J Clin Oncol, 24 Stopeck, 2002, Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies, Clin Cancer Res, 9, 2798 O’Donnell, 2005, A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points, Br J Cancer, 93, 876, 10.1038/sj.bjc.6602797 Cooney, 2005, A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck, Cancer Chemotherapy and Pharmacology, 55, 295, 10.1007/s00280-004-0871-5 Kuenen, 2002, Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors, J Clin Oncol, 15, 1657, 10.1200/JCO.20.6.1657 Aklilu, 2002, Toxicities of the antiangiogenic agent SU5416 in phase II studies, Proc Am Soc Clin Oncol Britten, 2002, Phase I trial of SU6668, a small molecule receptor tyrosine kinase inhibitor, given twice daily in patients with advanced cancers, Proc Am Soc Clin Oncol Kuenen, 2002, Dose finding study of SU6668 given thrice daily by oral route under fed conditions in patients with advanced malignancies, Proc Am Soc Clin Oncol Brahmer, 2002, A phase I study of SU6668 in patients with refractory solid tumors, Proc Am Soc Clin Oncol Murakami, 2003, Phase I, pharmacokinetic, and biological studies of TSU-68, the oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, administered after meals in patients with advanced solid tumors, Proc Am Soc Clin Oncol Xiong, 2004, A phase I surrogate endpoint study of SU6668 in patients with solid tumors, Invest New Drugs, 22, 459, 10.1023/B:DRUG.0000036688.96453.8d Sessa, 2006, Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing, Eur J Cancer, 42, 171, 10.1016/j.ejca.2005.09.033 Kuenen, 2005, Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies, Clin Cancer Res, 11, 6240, 10.1158/1078-0432.CCR-04-2466 Faivre, 2006, Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer, J Clin Oncol, 24, 25, 10.1200/JCO.2005.02.2194 Fiedler, 2005, A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease, Blood, 105, 986, 10.1182/blood-2004-05-1846 Socinski, 2006, Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC), Preliminary results of a multicenter phase II trial, J Clin Oncol, 24 Fiedler, 2005, A Phase I study of SU014813, a novel oral multi-targeted receptor tyrosine kinase (RTK) inhibitor, Clin Cancer Res, 11, 9061s Wakelee, 2005, A phase I dose escalation and pharmacokinetic study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL 647, in patients with advanced solid malignancies, J Clin Oncol, 23 Papadopoulos, 2005, A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor (SSKI), XL 999, in patients with advanced solid malignancies, Clin Cancer Res, 11, 9119s